Other Events ·
Nasdaq grants Vistagen Therapeutics a 180-day extension until February 2027 to regain compliance with the $1.00 minimum bid price requirement
VTGNVistagen Therapeutics, Inc.
Vistagen Therapeutics received a 180-day extension from Nasdaq until February 1, 2027, to regain compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market. The company has not yet regained compliance and intends to cure the deficiency within this period; failure to do so may result in delisting proceedings. Vistagen Therapeutics operates in the biotechnology industry, focusing on drug discovery and development.